Berkley Heights-based Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko, as its new chief financial officer.
Bayko brings over two decades of experience in biotechnology finance, strategy and capital markets to the clinical-stage biopharmaceutical company. She joins Kalaris from Evercore ISI, where she served as managing director and senior biotechnology analyst, recognized widely for her coverage of small- and mid-cap biotech firms. Her extensive career also includes senior analytical roles at JMP Securities, Next Generation Equity Research, Prudential Equity Group, and Baker Brothers Advisors, alongside foundational corporate strategy experience at Searle/Pharmacia.
The appointment comes at an operational stage for the company as it actively advances its clinical pipeline. Kalaris is currently enrolling patients in its Phase 1b/2 clinical study evaluating TH103, an investigational dual-targeting biologic designed for the treatment of neovascular Age-related Macular Degeneration (nAMD) and other prevalent retinal diseases.
“Liisa has extensive experience in assessing and valuing biotechnology companies, engaging the investor community, and navigating capital markets,” Andrew Oxtoby, president and CEO of Kalaris said. “She will be a valuable addition to our leadership team and will support Kalaris’ evolution as we advance clinical development efforts.”
Bayko holds a Bachelor of Science in Life Sciences from Queen’s University, a Master of Science in Medical Biophysics from the University of Toronto, and an MBA from the Kellogg School of Management at Northwestern University.
